Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation

Area of Science:

• Cardiology
• Pharmacology

Background:

• Oral anticoagulation is crucial for stroke prevention in nonvalvular atrial fibrillation (NVAF).
• Vitamin K antagonists (VKAs) are conventional but have limitations.
• Non-vitamin K antagonist oral anticoagulants (NOACs) offer alternatives, with direct factor Xa inhibitors like apixaban and edoxaban gaining prominence.

Purpose of the Study:

• To review and compare apixaban and edoxaban, two direct factor Xa inhibitors.
• To focus on their pharmacokinetic and pharmacodynamic profiles and drug interactions.
• To evaluate their efficacy and safety in NVAF patients using available clinical trial data and indirect comparisons.

Main Methods:

• Review of existing literature, focusing on Phase III clinical trials.
• Analysis of pharmacokinetic and pharmacodynamic data for apixaban and edoxaban.
• Indirect comparison of efficacy and safety data from separate clinical trials.

Main Results:

• Apixaban and edoxaban exhibit distinct pharmacokinetic and pharmacodynamic properties.
• Both agents have demonstrated significant efficacy in stroke prevention for NVAF patients.
• Safety profiles are generally favorable, with variations in bleeding risks that warrant careful consideration.

Conclusions:

• Apixaban and edoxaban represent important therapeutic options for stroke prevention in NVAF.
• Understanding their individual profiles is key for optimal clinical selection.
• Further research, including head-to-head trials, would enhance comparative understanding of NOACs.